Abstract
The possibility that HRT may increase the risk of cancer, female cancers in particular, has been a general concern ever since HRT was first advocated in the mid-1950s. For cancer of the uterus that concern was vindicated when it was shown that unopposed estrogens greatly increase the risk. However, because HRT is undoubtedly effective in relieving menopausal symptoms, and because it was thought that HRT may reduce the risk of coronary heart disease, the use of estrogens in combination with progestins soon supplanted unopposed estrogen use (if less so among women who had undergone hysterectomies), in the belief, soon confirmed by epidemiological evidence, that combined therapy probably eliminates any increase in the risk of uterine cancer, or perhaps even reduces it.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Banks, E., Beral, V., Cameron, R., et al. (2001). Breast Cancer Research, http://breast-cancer-research.com/content/4/1/R1.
Barrett-Connor, E. (1991). Ann. Int. Med. 115, 455–456.
Beral, V., Banks, E., Reeves, G., and Bull, D. (2002). Lancet 362, 1330–1331.
Castellague, J., Perez-Gutthann, S., and Garcia Rodriguez, L. A. (1998). Drug Safety 18, 117–123.
Chlebowski, R. T., Hendrix, S. L., Langer, R. D., et al. (2003). JAMA 289, 3243–3253.
Collaborative Group on Hormonal Factors in Breast Cancer. (1997). Lancet 350, 1047–1959.
Greendale, G. A., Reboussin, B. A., Sie, A., et al. (1999). Ann. Int. Med. 362, 419–427.
Grodstein, F., Newcomb, P. A., and Stampfer, M. J. (1999). Am. J. Med. 106, 574–582.
Hill, D. A., Weiss, N. S., Beresford, S. A.A., et al. (2000). Am. J. Obstset. Gynecol. 183, 1456–1461.
Hulley, S. B. and Grady, D. (2004). JAMA 291, 1769–1771.
Magnusson, C., Baron, J. A., Correia, N., Bergstrom, R., Adami, H.-O., and Persson, I. (1999). Int. J. Cancer 81, 339–344.
Manson, J. E., Hsia, J., Johnson, K. C. et al. (2003). JAMA 289, 3243–3253.
Million Women Study Collaborators. (2003). Lancet 362, 419–427.
Million Women Study Collaborators. (2003). Lancet 362, 1160.
Morrison, A. S., Brisson, J., and Khalid, N. (1988). J. Natl. Cancer Inst. 80, 1540–1547.
Shapiro, S., Slone, D., Kaufman, D. W. et al. (1980). N. Engl. J. Med. 303, 485–489.
Shapiro, S. (2000). Am. J. Epidemiol. 151, 939–945.
Shapiro, S. (2003). Climacteric 6, 302–310.
Shapiro, S. (2004). Climacteric 7, 3–7.
Stampfer, M. and Colditz, G. (1991). Prev. Med. 20, 47–63.
Tang, M. X., Jacobs, D., Stern, Y., et al. (1996). Lancet 348, 429–432.
The Women’s Health Initiative Steering Committee. (2004). JAMA 291, 1701–1712.
Weiss, N. S., Ure, C. L., Ballard, J. H., et al. (1980). N. Engl. J. Med. 303, 1195–1198.
Writing Group for the Women’s Health Initiative Investigators. (2003). JAMA 228, 321–333.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shapiro, S. Adverse neoplastic and cardiovascular outcomes of HRT. Endocr 24, 203–210 (2004). https://doi.org/10.1385/ENDO:24:3:203
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:24:3:203